维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Peter RY"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Expression of interleukin-6, c-fos, and zif268 mRNAs in rat ischemic cortex显示文摘	Xinkang W Tian-Li Peter RY	1995	J Cereb Blood Flow Metab1995，15，：	1
	2	Floral volatiles ofTanacetum vulgare L. attractive toLobesia botrana den. et schiff. females显示文摘	Bruno Gabel Denis Thiéry Vaclav Suchy Frédéric Marion-Poll Peter Hradsky Pavel Farkas	1992	Journal of Chemical Ecology1992，，5：	1
	3	Deformation behavior of root dentin under Sjoegren's syndrome 显示文摘	Dmit ry Zayt sev Sergei Grigoriev Peter Panfilov	2011	Materials Letters2011，65，1516：	1
	4	Plant proteins in relation to human protein and amino acid nutrition显示文摘	Vernon RY Peter LP	1994	The American Journal of Clinical Nutrition1994，，：	1
	5	In-situ three-dimensional microstructural investigation of solidification of an Al-Cu alloy by ultrafast x-ray microtomography显示文摘	Olivire Ludwig Marco Dimichiel Luc Salvo Michel Suéry Peter Falus	2005	Metallurgical and Materials Transactions A2005，，6：	1
	6	Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration 显示文摘	John RW Judithann ML Peter RY	1998	J Biol Chem1998，273，10：	1
	7	Multiple sclerosis drug repurposing for neuroregeneration显示文摘Multiple sclerosis(MS)is an autoimmune disorder of the central nervous system(CNS)and is primarily characterized by immune cell infiltration leading to relapses followed by remission phases and a disease course turning progressive over time with neurodegenerative processes taking over(Amin and Hersh,2023).Of note,beyond relapse-associated worsening early in disease progression independent of relapse activity may arise independently of relapse activity and can occur in all phenotypes.Autoimmune-mediated damage of myelin sheaths and the subsequent loss of mature oligodendrocytes are resulting in impaired axonal integrity,neurodegeneration and accounts for irreversible neuronal damage(Kuhlmann et al.,2023).The current landscape of available disease-modifying therapies comprises mainly immunomodulatory drugs that effectively diminish relapses and slow down progression at the onset form of the disease,namely relapsing MS(RMS).In this regard,a number of drugs have been approved as disease-modifying therapies for MS by US Food and Drug Administration and European Medicines Agencies(Box 1).	Peter Göttle Michael Dietrich Patrick Küry	2024	Neural Regeneration Research2024，19，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费